VIRI News and Press, Virios Therapeutics Inc. From 09/19/22

Clinical-stage biotech Virios Therapeutics, Inc. ( NASDAQ: VIRI ) announced Monday that the company’s lead candidate, IMC-1, did not achieve statistical significance for the main goal in its Phase 2b trial involving patients with fibromyalgia. The FORTRESS study, desi...

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced topline results from its FORT...

NEW YORK, Sept. 16, 2022 (GLOBE NEWSWIRE) -- FMW Media's New to The Street / Newsmax TV announces the broadcasting line-up of its national syndicated 1-hour TV show this Sunday, September 18, 2022, airing time 10-11 AM ET. New to The Street's 386th TV episode l...

NEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- FMW Media’s New to The Street TV , a nationally syndicated TV show, announces episode #384, airing on Fox Business Network tonight, Monday, September 12, 2022, at 10:30 PM PT. The New to The Street show wi...

Virios Therapeutics ( NASDAQ: VIRI ) said enrollment in an exploratory Long-COVID trial began and the first patient was dosed. The study is supported via an investigational grant to the Bateman Horne Center, the company noted in an Aug. 15 press release. The compan...

-New Long-COVID Research Program Complements Fibromyalgia Phase 2b Clinical Research Program- Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating ch...

Virios Therapeutics, Inc. (VIRI) Q2 2022 Earnings Conference Call August 11, 2022 8:30 a.m. ET CompanyParticipants Greg Duncan - CEO Ralph Grosswald - SVP, Operations Angela Walsh - SVP, Finance & Treasurer Conference Call Participants David Bautz...

Virios Therapeutics press release ( NASDAQ: VIRI ): Q2 GAAP EPS of -$0.44 beats by $0.07 . As of June 30, 2022, Virios Therapeutics’ cash totaled $7.7 million. The Company believes it will have sufficient resources to fund its planned operations through the ...

- Top Line FORTRESS Study Data Expected in September 2022 - - Conference Call Today at 8:30 a.m. ET - Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilita...

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia , today announced that Greg Duncan, Chairman and CEO of Virios Ther...